Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.54 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14534189 | 0.86 | OPRM1 (0.71) | HSD11B1OPRM1OPRD1OPRK1ADRA1A | |
| SCHEMBL8351817 | 0.85 | HSD11B1 (0.60) | HSD11B1OPRM1OPRD1OPRK1ADRA1A | |
| SCHEMBL349195 | 0.85 | MEN1 (0.56) | HSD11B1OPRM1OPRD1OPRK1ADRA1A | |
| Hydrochloric Acid SCHEMBL8348521 | 0.84 | HSD11B1 (0.59) | HSD11B1OPRM1OPRD1OPRK1ADRA1A | |
| SCHEMBL4669195 | 0.84 | OPRM1 (0.50) | OPRM1OPRD1OPRK1ADRA1ASLC22A1 | |
| SCHEMBL14507954 | 0.82 | CYP2D6 (0.55) | HSD11B1OPRM1OPRD1OPRK1ADRA1A | |
| SCHEMBL2481767 | 0.82 | AKR1C1 (0.58) | HSD11B1OPRM1OPRD1OPRK1ADRA1A | |
| SCHEMBL27683261 | 0.82 | AKR1C1 (0.63) | HSD11B1OPRM1OPRD1OPRK1ADRA1A | |
| SCHEMBL1041983 | 0.82 | AKR1C1 (0.63) | HSD11B1MEN1KMT2ACHRM3 | |
| Iodomethane SCHEMBL3898463 | 0.82 | MEN1 (0.53) | HSD11B1OPRM1OPRD1OPRK1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872006-B2 | Pyrazole compounds having cannabinoid receptor (CB1) antagonizing activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1951678-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007046550-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| CN-1254467-C | Preparation method of 4-methylamino-4-phenylpiperidine | SANOFI SYNTHELABO (FR) | 2006-05-03 | — | — | CN | disclosed |
| CN-1527817-A | Preparation method of 4-methylamino-4-phenylpiperidine | ����ɳŵ��-����������˾ | 2004-09-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | HSD11B1 1424/4885OPRM1 79/4885OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.